FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565783492> ?p ?o ?g. }

• W2565783492 endingPage "10212" @default.
• W2565783492 startingPage "10199" @default.
• W2565783492 abstract "// Caroline Fanja Razafinjatovo 1 , Daniel Stiehl 2 , Eva Deininger 1 , Markus Rechsteiner 1 , Holger Moch 1 , Peter Schraml 1 1 Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland 2 Institute of Physiology and Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland Correspondence to: Peter Schraml, email: peter.schraml@usz.ch Keywords: clear cell renal cell carcinoma, VHL missense mutations, pVHL binding sites, p53, HIFα Received: July 22, 2016     Accepted: December 15, 2016     Published: December 30, 2016 ABSTRACT Clear cell Renal Cell Carcinoma (ccRCC) formation is connected to functional loss of the von Hippel-Lindau ( VHL ) gene. Recent data identified its gene product, pVHL, as a multifunctional adaptor protein which interacts with HIFα subunits but also with the tumor suppressor p53. p53 is hardly expressed and rarely mutated in most ccRCC. We showed that low and absent p53 expression correlated with the severity of VHL mutations in 262 analyzed ccRCC tissues. In contrast to nonsense and frameshift mutations which abrogate virtually all pVHL functions, missense mutations may rather influence one or few functions. Therefore, we focused on four VHL missense mutations, which affect the overlapping pVHL binding sites of p53 and Elongin C, by investigating their impact on HIFα degradation, p53 expression and signaling, as well as on cellular behavior using ccRCC cell lines and tissues. TP53 mRNA and its effector targets p21 , Bax and Noxa , were altered both in engineered cell lines and in tumor tissues which carried the same missense mutations. Two of these mutations were not able to degrade HIFα whereas the remaining two mutations led to HIFα downregulation, suggesting the latter are p53 binding site-specific. The selected VHL missense mutations further enhanced tumor cell survival, but had no effects on cell proliferation. Whereas Sunitinib was able to efficiently reduce cell proliferation, Camptothecin was additionally able to increase apoptotic activity of the tumor cells. It is concluded that systematic characterization of the VHL mutation status may help optimizing targeted therapy for patients with metastatic ccRCC." @default.
• W2565783492 created "2017-01-06" @default.
• W2565783492 creator A5015571067 @default.
• W2565783492 creator A5021128098 @default.
• W2565783492 creator A5038532092 @default.
• W2565783492 creator A5044316608 @default.
• W2565783492 creator A5053110552 @default.
• W2565783492 creator A5076510325 @default.
• W2565783492 date "2016-12-30" @default.
• W2565783492 modified "2023-09-24" @default.
• W2565783492 title "<i>VHL</i> missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma" @default.
• W2565783492 cites W144803921 @default.
• W2565783492 cites W1510245258 @default.
• W2565783492 cites W1536258007 @default.
• W2565783492 cites W1965847750 @default.
• W2565783492 cites W1971026321 @default.
• W2565783492 cites W1973532066 @default.
• W2565783492 cites W1975160071 @default.
• W2565783492 cites W1976902658 @default.
• W2565783492 cites W1991408439 @default.
• W2565783492 cites W1991930213 @default.
• W2565783492 cites W2000944914 @default.
• W2565783492 cites W2001212363 @default.
• W2565783492 cites W2016751490 @default.
• W2565783492 cites W2017239168 @default.
• W2565783492 cites W2021793290 @default.
• W2565783492 cites W2031019010 @default.
• W2565783492 cites W2040855644 @default.
• W2565783492 cites W2046511043 @default.
• W2565783492 cites W2063204257 @default.
• W2565783492 cites W2073939107 @default.
• W2565783492 cites W2076645574 @default.
• W2565783492 cites W2078123480 @default.
• W2565783492 cites W2080237506 @default.
• W2565783492 cites W2082184716 @default.
• W2565783492 cites W2087145462 @default.
• W2565783492 cites W2087841059 @default.
• W2565783492 cites W2089346177 @default.
• W2565783492 cites W2089584150 @default.
• W2565783492 cites W2094518946 @default.
• W2565783492 cites W2103214205 @default.
• W2565783492 cites W2107319630 @default.
• W2565783492 cites W2107838011 @default.
• W2565783492 cites W2108366666 @default.
• W2565783492 cites W2124406670 @default.
• W2565783492 cites W2124448303 @default.
• W2565783492 cites W2136664272 @default.
• W2565783492 cites W2156038562 @default.
• W2565783492 cites W2157641713 @default.
• W2565783492 cites W2161057270 @default.
• W2565783492 cites W2161140793 @default.
• W2565783492 cites W2161609794 @default.
• W2565783492 cites W2169093447 @default.
• W2565783492 cites W2169246212 @default.
• W2565783492 cites W2284518822 @default.
• W2565783492 cites W2335203792 @default.
• W2565783492 cites W2344164335 @default.
• W2565783492 cites W2412152821 @default.
• W2565783492 cites W2510809074 @default.
• W2565783492 cites W341651751 @default.
• W2565783492 doi "https://doi.org/10.18632/oncotarget.14372" @default.
• W2565783492 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5354652" @default.
• W2565783492 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28052007" @default.
• W2565783492 hasPublicationYear "2016" @default.
• W2565783492 type Work @default.
• W2565783492 sameAs 2565783492 @default.
• W2565783492 citedByCount "10" @default.
• W2565783492 countsByYear W25657834922018 @default.
• W2565783492 countsByYear W25657834922019 @default.
• W2565783492 countsByYear W25657834922020 @default.
• W2565783492 countsByYear W25657834922021 @default.
• W2565783492 countsByYear W25657834922022 @default.
• W2565783492 crossrefType "journal-article" @default.
• W2565783492 hasAuthorship W2565783492A5015571067 @default.
• W2565783492 hasAuthorship W2565783492A5021128098 @default.
• W2565783492 hasAuthorship W2565783492A5038532092 @default.
• W2565783492 hasAuthorship W2565783492A5044316608 @default.
• W2565783492 hasAuthorship W2565783492A5053110552 @default.
• W2565783492 hasAuthorship W2565783492A5076510325 @default.
• W2565783492 hasBestOaLocation W25657834921 @default.
• W2565783492 hasConcept C104317684 @default.
• W2565783492 hasConcept C142724271 @default.
• W2565783492 hasConcept C2777472916 @default.
• W2565783492 hasConcept C2778264664 @default.
• W2565783492 hasConcept C2781278892 @default.
• W2565783492 hasConcept C29906990 @default.
• W2565783492 hasConcept C501734568 @default.
• W2565783492 hasConcept C502942594 @default.
• W2565783492 hasConcept C54355233 @default.
• W2565783492 hasConcept C555283112 @default.
• W2565783492 hasConcept C71924100 @default.
• W2565783492 hasConcept C75563809 @default.
• W2565783492 hasConcept C86803240 @default.
• W2565783492 hasConceptScore W2565783492C104317684 @default.
• W2565783492 hasConceptScore W2565783492C142724271 @default.
• W2565783492 hasConceptScore W2565783492C2777472916 @default.
• W2565783492 hasConceptScore W2565783492C2778264664 @default.
• W2565783492 hasConceptScore W2565783492C2781278892 @default.

• next